Navigation Links
Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
Date:4/2/2009

SEATTLE, April 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that on April 2, 2009, CTI received notice from The NASDAQ Stock Market ("NASDAQ") indicating that the company has evidenced full compliance with all applicable requirements for continued listing on The NASDAQ Capital Market. The notice followed CTI's compliance with the minimum $35 million market value of listed securities requirement for a minimum of ten consecutive trading days, as required by Marketplace Rule 4310(c)(3). As of April 1, 2009, the company's market capitalization was $113,287,573.

"We are pleased to have regained compliance with The NASDAQ Capital Market listing standards as the result of the increase in our share price, which we believe is attributable to the progress we continue to make in our drug development programs," said James A. Bianco, M.D., CEO of Cell Therapeutics. "We look forward to adding greater shareholder value through our submission of a New Drug Application (NDA) for pixantrone for aggressive relapse non-Hodgkin's lymphoma in the second quarter of 2009 and potential approval this year, in addition to other strategic business initiatives we are currently pursuing."

As disclosed on September 6, 2008 and October 10, 2008, the company was previously notified by NASDAQ regarding its non-compliance with the $50 million market value of listed securities requirement for continued listing on The NASDAQ Global Market. At the company's request, on January 6, 2009, the NASDAQ Listing Qualifications Panel determined to transfer the listing of the company's common stock from The NASDAQ Global Market to The NASDAQ Capital Market, subject to the company demonstrating compliance with all applicable requirements for continued listing on The NASDAQ Capital Market, which deadline was extended to April 6, 2009. The matter is now closed.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These risks and uncertainties include, without limitation, the Company's ability to sustain compliance with the NASDAQ Capital Market's continued listing requirements, as well as other risks and uncertainties that could affect the Company's business operations and the development of the Company's products including the Company's ability to raise additional capital to fund its continued operations, risks associated with preclinical and clinical developments in the biopharmaceutical industry in general including, without limitation ,the Company's ability to submit an NDA in the first half of 2009 for pixantrone and gain approval in 2009, the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling pixantrone. You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T : 206.272.4347
    F : 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
2. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
3. Arno Therapeutics Reports 2008 Year-End Financial Results
4. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
5. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
6. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
7. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
8. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
9. Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure
10. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
11. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):